Headlines about Mesa Laboratories (NASDAQ:MLAB) have been trending somewhat positive this week, according to Accern. The research firm scores the sentiment of media coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Mesa Laboratories earned a news sentiment score of 0.06 on Accern’s scale. Accern also gave media headlines about the medical instruments supplier an impact score of 45.945992548799 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Here are some of the media headlines that may have effected Accern’s analysis:
- Mesa Laboratories (MLAB) & Fortive (FTV) Head to Head Comparison (americanbankingnews.com)
- Mesa Laboratories (MLAB) Cut to “Sell” at BidaskClub (americanbankingnews.com)
- TheStreet Lowers Mesa Laboratories (MLAB) to C+ (americanbankingnews.com)
- Zacks: Mesa Laboratories, Inc. (MLAB) Given Average Recommendation of “Strong Buy” by Brokerages (americanbankingnews.com)
- Mesa Laboratories (MLAB) Rating Lowered to Strong Sell at Zacks Investment Research (americanbankingnews.com)
A number of research firms recently issued reports on MLAB. ValuEngine upgraded shares of Mesa Laboratories from a “hold” rating to a “buy” rating in a report on Monday, April 2nd. TheStreet downgraded shares of Mesa Laboratories from a “b-” rating to a “c” rating in a report on Wednesday, February 7th. BidaskClub upgraded shares of Mesa Laboratories from a “hold” rating to a “buy” rating in a report on Thursday, March 15th. Finally, Zacks Investment Research downgraded shares of Mesa Laboratories from a “hold” rating to a “sell” rating in a report on Saturday, February 10th.
Mesa Laboratories stock traded up $0.35 during trading on Tuesday, reaching $170.00. The company had a trading volume of 1,261 shares, compared to its average volume of 17,757. Mesa Laboratories has a 12-month low of $122.35 and a 12-month high of $170.69. The company has a market cap of $636.29, a price-to-earnings ratio of 40.28 and a beta of 0.50. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.64 and a current ratio of 2.37.
Mesa Laboratories (NASDAQ:MLAB) last released its earnings results on Monday, February 5th. The medical instruments supplier reported ($0.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.53 by ($0.77). Mesa Laboratories had a negative net margin of 3.82% and a positive return on equity of 9.20%. The company had revenue of $23.67 million during the quarter, compared to analysts’ expectations of $23.10 million. sell-side analysts predict that Mesa Laboratories will post 5.66 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 15th. Shareholders of record on Thursday, May 31st will be paid a dividend of $0.16 per share. The ex-dividend date of this dividend is Wednesday, May 30th. This represents a $0.64 annualized dividend and a yield of 0.38%. Mesa Laboratories’s dividend payout ratio is currently 15.17%.
In other Mesa Laboratories news, Director John Bradley Schmieder sold 3,000 shares of the business’s stock in a transaction that occurred on Thursday, February 8th. The shares were sold at an average price of $132.27, for a total transaction of $396,810.00. Following the completion of the sale, the director now directly owns 77,869 shares in the company, valued at $10,299,732.63. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Robert V. Dwyer sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, March 14th. The stock was sold at an average price of $144.01, for a total transaction of $720,050.00. Following the sale, the director now owns 68,521 shares of the company’s stock, valued at $9,867,709.21. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 12,000 shares of company stock valued at $1,668,860. 15.70% of the stock is owned by insiders.
TRADEMARK VIOLATION NOTICE: This article was reported by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are viewing this article on another website, it was copied illegally and reposted in violation of US & international copyright & trademark law. The correct version of this article can be viewed at https://www.thelincolnianonline.com/2018/04/17/mesa-laboratories-mlab-given-media-impact-score-of-0-06.html.
Mesa Laboratories Company Profile
Mesa Laboratories, Inc designs, manufactures, and markets quality control instruments and disposable products. The company's Instruments segment offers data loggers, which are precision instruments used in critical manufacturing, quality control, and validation applications; medical meters and calibration solutions used to test various parameters of the dialysis fluid, and the calibration and operation of the dialysis machine; gas flow calibration and air sampling equipment that are used for industrial hygiene assessments, calibration of gas metering equipment, and environmental air monitoring; and torque testing systems used for measure bottle cap tightness.
Receive News & Ratings for Mesa Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesa Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.